Resolution of chronic hepatitis delta infection after five years of peginterferon-adefovir: Lessons from a case report

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 3, 2013, Pages

  Brichler, Ségolène ^a   Setshedi, Mashiko ^b   Renou, Christophe ^c  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Hyeres Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENVELOPE PROTEIN; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DELTA AGENT HEPATITIS; DRUG DEPENDENCE; DRUG MONITORING; GENOTYPE; HEPATITIS DELTA VIRUS; HUMAN; LIMIT OF DETECTION; LIVER HISTOLOGY; MALE; PHYLOGENY; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; TREATMENT DURATION;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS D, CHRONIC; HEPATITIS DELTA ANTIGENS; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RNA, VIRAL;

EID: 84878931740     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.01.002     Document Type: Article

References (19)

1. Romeo R., Colombo M. Treatment of chronic hepatitis delta: mission impossible?. Gastroenterology 2011, 141:2268-2271.
2. Wedemeyer H., Manns M.P. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010, 7:31-40.
3. Le Gal F., Gordien E., Affolabi D., Hanslik T., Alloui C., Deny P., et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005, 43:2363-2369.
4. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-684.
5. European Association for the Study of the Liver E.A.S.L. Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
6. Hoofnagle J.H., di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 1997, 336:347-356.
7. Castelnau C., Le Gal F., Ripault M.P., Gordien E., Martinot-Peignoux M., Boyer N., et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44:728-735.
8. Niro G.A., Ciancio A., Gaeta G.B., Smedile A., Marrone A., Olivero A., et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006, 44:713-720.
9. Gunsar F., Akarca U.S., Ersoz G., Kobak A.C., Karasu Z., Yuce G., et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005, 10:721-726.
10. Yurdaydin C., Bozkaya H., Onder F.O., Senturk H., Karaaslan H., Akdogan M., et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon. J Viral Hepat 2008, 15:314-321.
11. Wedemeyer H., Yurdaydin C., Dalekos G.N., Erhardt A., Cakaloglu Y., Degertekin H., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011, 364:322-331.
12. Mansour W., Ducancelle A., Le Gal F., Le Guillou-Guillemette H., Abgueguen P., Pivert A., et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010, 47:97-99.
13. Farci P., Roskams T., Chessa L., Peddis G., Mazzoleni A.P., Scioscia R., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126:1740-1749.
14. Mederacke I., Yurdaydin C., Dalekos G.N., Bremer B., Erhardt A., Cakaloglu Y., et al. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha2a treatment. Antivir Ther 2012, 17:305-312.
15. Manesis E.K., Schina M., Le Gal F., Agelopoulou O., Papaioannou C., Kalligeros C., et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 2007, 12:381-388.
16. Deguchi M., Yamashita N., Kagita M., Asari S., Iwatani Y., Tsuchida T., et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004, 115:217-222.
17. Moucari R., Korevaar A., Lada O., Martinot-Peignoux M., Boyer N., Mackiewicz V., et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009, 50:1084-1092.
18. Tangkijvanich P., Komolmit P., Mahachai V., Sa-nguanmoo P., Theamboonlers A., Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009, 46:117-123.
19. Zachou K., Yurdaydin C., Drebber U., Dalekos G.N., Erhardt A., Cakaloglu Y., et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010, 30:430-437.